⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12863970 | 0.74 | LYN (0.44) | — | |
| Guanine SCHEMBL14796943 | 0.72 | HSD17B10 (0.48) | — | |
| SCHEMBL24823866 | 0.71 | — | — | |
| SCHEMBL11884072 | 0.71 | LYN (0.68) | — | |
| SCHEMBL1684202 | 0.70 | — | — | |
| SCHEMBL4422067 | 0.70 | — | — | |
| SCHEMBL4760133 | 0.70 | — | — | |
| SCHEMBL634296 | 0.70 | — | — | |
| SCHEMBL6526251 | 0.70 | — | — | |
| SCHEMBL7443218 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270953-B1 | NOVEL TREATMENT METHOD | IDOGEN AB (SE) | 2021-07-07 | — | — | EP | claimed |
| CN-111995623-A | Synthesis method of 7-bromo-4-chloro-1-methyl-1H-imidazo [4,5-c ] pyridine | 上海毕得医药科技有限公司 | 2020-11-27 | — | — | CN | claimed |
| CN-111995583-A | Synthesis method of 1, 5-dimethylpyrimidine-2 (1H) -ketone | 上海毕得医药科技有限公司 | 2020-11-27 | — | — | CN | claimed |
| EP-3431484-A1 | A FLUORESCENT CYCLIC DINUCLEOTIDE AND ITS USE IN METHODS OF IDENTIFYING SUBSTANCES HAVING AN ABILITY TO MODULATE THE CGAS/STING PATHWAY | Ludwig-Maximilians-Universität München (DE) | 2019-01-23 | — | — | EP | claimed |
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | claimed |
| EP-2560982-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | Chemgenes Corporation (US) | 2013-02-27 | — | — | EP | claimed |
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | claimed |
| EP-2398815-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | Chemgenes Corporation (US) | 2011-12-28 | — | — | EP | claimed |
| US-20110300142-A1 | USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | IDOGEN AB (SE) | 2011-12-08 | — | — | US | claimed |
| WO-2011103468-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | CHEMGENES CORPORATION (US) | 2011-08-25 | — | — | WO | claimed |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | CHEMGENES CORPORATION (US) | 2011-06-09 | — | — | US | claimed |
| WO-2010096201-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION (US) | 2010-08-26 | — | — | WO | claimed |
| EP-2164500-A1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | Idogen AB (SE) | 2010-03-24 | — | — | EP | claimed |
| US-20090054250-A1 | Methods to create fluorescent biosensors using aptamers with fluorescent base analogs | ARIZONA BOARD OF REGENTS, A CORPORATE BODY ORGANIZED UNDER ARIZONA LAW, ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY | 2009-02-26 | — | — | US | claimed |
| WO-2008147283-A1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | SALFORD LEIF (SE) | 2008-12-04 | — | — | WO | claimed |
| WO-2006078337-A2 | METHODS TO CREATE FLUORESCENT BIOSENSORS USING APTAMERS WITH FLUORESCENT BASE ANALOGS | THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2006-07-27 | — | — | WO | claimed |
| EP-0132127-B1 | CYCLIC UREA CONDENSATES, TEXTILE AND PAPER TREATING COMPOSITIONS AND NOVEL CYCLIC UREAS | SEQUA CHEMICALS INC. (US) | 1993-02-03 | — | — | EP | claimed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | claimed |
| EP-0132127-A2 | Cyclic urea condensates, textile and paper treating compositions and novel cyclic ureas | SEQUA CHEMICALS INC. (US) | 1985-01-23 | — | — | EP | claimed |
| CN-122036680-A | Anti-fibrotic pyridones | 英特穆恩公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12351583-B2 | Triazolopyrimidines based on thymine nucleobase and methods for producing them | CHEMITERAS, INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119119156-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-12-13 | — | — | CN | disclosed |
| US-20240391945-A1 | NUCLEIC ACID SYNTHESIS METHOD USING SEGMENT-TYPE AMIDITE | NITTO DENKO CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-112996522-B | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-09-20 | — | — | CN | disclosed |
| US-20240294924-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-05 | — | — | US | disclosed |
| EP-4398254-A2 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | Memorial Sloan Kettering Cancer Center (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-117964674-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964673-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-20240140983-A1 | SINGLE STRANDED DNA ENZYME INHIBITORS | MASSEY UNIVERSITY (NZ) | 2024-05-02 | — | — | US | disclosed |
| EP-2991655-B1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117795071-A | Antisense oligonucleotides for preventing renal dysfunction caused by endothelial dysfunction through inhibition of ephrin-B2 | 马克斯·普朗克科学促进学会 | 2024-03-29 | — | — | CN | disclosed |
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-4297873-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Tyra Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230218632-A1 | CYCLIC SULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-11530207-B2 | Compounds for the treatment of cancer | SKYHAWK THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022253167-A1 | SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| EP-4089099-A1 | NUCLEIC ACID SYNTHESIS METHOD USING SEGMENT-TYPE AMIDITE | Nitto Denko Corporation (JP) | 2022-11-16 | — | — | EP | disclosed |
| CN-115315430-A | Nucleic acid synthesis method using segmented phosphoramidite compound | 日东电工株式会社 | 2022-11-08 | — | — | CN | disclosed |
| US-11447520-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | TRANSLATE BIO, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-110452216-B | Anti-fibrotic pyridinones | 英特穆恩公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-4047005-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | Daiichi Sankyo Company, Limited (JP) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022162536-A1 | SINGLE STRANDED DNA ENZYME INHIBITORS | MASSEY UNIVERSITY (NZ) | 2022-08-04 | — | — | WO | disclosed |
| US-20220194950-A1 | TRIAZOLOPYRIMIDINES BASED ON THYMINE NUCLEOBASE AND METHODS FOR PRODUCING THEM | TERA STONE CO., LTD (JP) | 2022-06-23 | — | — | US | disclosed |
| WO-2022129281-A1 | NITROGEN CONTAINING 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| CN-114502565-A | Process for producing bicyclic phosphoramidites | 第一三共株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3950064-A1 | THYMINE NUCLEOBASE-BASED TRIAZOLOPYRIMIDINES AND PRODUCTION METHOD THEREFOR | Tera Stone Co., Ltd (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-11162101-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210292316-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | SKYHAWK THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2021188911-A1 | CYCLIC SULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11091475-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2021141072-A1 | NUCLEIC ACID SYNTHESIS METHOD USING SEGMENT-TYPE AMIDITE | 日東電工株式会社 | 2021-07-15 | — | — | WO | disclosed |
| EP-3270953-B1 | NOVEL TREATMENT METHOD | IDOGEN AB (SE) | 2021-07-07 | — | — | EP | disclosed |
| WO-2021121327-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-11014956-B2 | Compositions and methods for altering second messenger signaling | Memorial Sloan Kettering Cancer Center; The Rockefeller (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2021080021-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | 日東電工株式会社 | 2021-04-29 | — | — | WO | disclosed |
| CN-112386604-A | Modulators of cGAS | 纪念斯隆-凯特琳癌症中心 | 2021-02-23 | — | — | CN | disclosed |
| US-10898474-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3333157-B1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | HARBIN ZHENBAO PHARMACEUTICAL CO LTD (CN) | 2020-12-23 | — | — | EP | disclosed |
| CN-111995583-A | Synthesis method of 1, 5-dimethylpyrimidine-2 (1H) -ketone | 上海毕得医药科技有限公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-2903991-B1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200277378-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2020-09-03 | — | — | US | disclosed |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| WO-2020154321-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-110974981-A | Compositions and methods for delivering messenger RNA | 野草莓树生物制药公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20200078453-A1 | METHODS OF TREATING A MAMMAL SUFFERING FROM OR SUSCEPTIBLE TO AN IMMUNE REACTION TO DRUG TREATMENT | IDOGEN AB (SE) | 2020-03-12 | — | — | US | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10519133-B2 | Vinyl compounds as FGFR and VEGFR inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2019-12-31 | — | — | US | disclosed |
| US-10508276-B2 | Methods and compositions for the production of siRNAs | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190330257-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-10-31 | — | — | US | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10385091-B2 | Compositions and methods for altering second messenger signaling | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-08-20 | — | — | US | disclosed |
| US-10376497-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10233195-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3431484-A1 | A FLUORESCENT CYCLIC DINUCLEOTIDE AND ITS USE IN METHODS OF IDENTIFYING SUBSTANCES HAVING AN ABILITY TO MODULATE THE CGAS/STING PATHWAY | Ludwig-Maximilians-Universität München (DE) | 2019-01-23 | — | — | EP | disclosed |
| US-10131686-B2 | Compositions and methods for altering second messenger signaling | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180273950-A1 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF SIRNAS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180222886-A1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2018-08-09 | — | — | US | disclosed |
| US-20180222886-A1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2018-08-09 | — | — | US | disclosed |
| EP-3348564-A1 | PROCESS FOR PREPARING PHOSPHATE COMPOUND BEARING ISOTOPE | Bonac Corporation (JP) | 2018-07-18 | — | — | EP | disclosed |
| US-20180169063-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2018-06-21 | — | — | US | disclosed |
| US-20180169063-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2018-06-21 | — | — | US | disclosed |
| EP-3333157-A1 | VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2018-06-13 | — | — | EP | disclosed |
| US-20180127454-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-10 | — | — | US | disclosed |
| US-20180118777-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER | 2018-05-03 | — | — | US | disclosed |
| US-9931317-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2018-04-03 | — | — | US | disclosed |
| US-9931317-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2018-04-03 | — | — | US | disclosed |
| CN-107814673-A | The manufacture method of phosphate cpd with isotope | 株式会社博纳克 | 2018-03-20 | — | — | CN | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| CN-107759650-A | The manufacture method of phosphate cpd with isotope | 株式会社博纳克 | 2018-03-06 | — | — | CN | disclosed |
| EP-3270953-A1 | NOVEL TREATMENT METHOD | Idogen AB (SE) | 2018-01-24 | — | — | EP | disclosed |
| US-9840533-B2 | Compositions and methods for altering second messenger signaling | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840703-B2 | Methods and compositions for the production of siRNAs | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3238726-A2 | COMPOSITION COMPRISING INTERFERON GAMMA AND AN HDAC INHIBITOR OR GONADOTROPIN RECEPTOR SIGNALLING HORMONE | Idogen AB (SE) | 2017-11-01 | — | — | EP | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170112805-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-20170112805-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| EP-2654758-B1 | A COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3-DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR IMMUNE REJECTION OF ORGANS | IDOGEN AB (SE) | 2017-04-19 | — | — | EP | disclosed |
| EP-3126362-A1 | ANTI-FIBROTIC PYRIDINONES | Intermune, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-2326656-B1 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORP (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20170014499-A1 | NOVEL TREATMENT METHOD | IDOGEN AB (SE) | 2017-01-19 | — | — | US | disclosed |
| WO-2016177686-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016146842-A1 | NOVEL TREATMENT METHOD | IDOGEN AB (SE) | 2016-09-22 | — | — | WO | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160184265-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-20160184265-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160130259-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9321746-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9321746-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9315799-B2 | Process for preparing phosphate compound bearing isotope | BONAC CORPORATION (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20160068560-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068809-A1 | USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | IDOGEN AB (SE) | 2016-03-10 | — | — | US | disclosed |
| EP-2991655-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | Memorial Sloan Kettering Cancer Center (US) | 2016-03-09 | — | — | EP | disclosed |
| CN-105358158-A | Compositions and methods for altering second messenger signaling | SLOAN KETTERING INST CANCER | 2016-02-24 | — | — | CN | disclosed |
| US-20150361065-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2015-12-17 | — | — | US | disclosed |
| US-20150361065-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2015-12-17 | — | — | US | disclosed |
| US-20150337306-A1 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF SIRNAS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-26 | — | — | US | disclosed |
| WO-2015153683-A1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150266899-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2015-09-24 | — | — | US | disclosed |
| EP-2903991-A1 | ANTI-FIBROTIC PYRIDINONES | Intermune, Inc. (US) | 2015-08-12 | — | — | EP | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| CN-104822687-A | Anti-fibrotic pyridinones | INTERMUNE INC | 2015-08-05 | — | — | CN | disclosed |
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| CN-102124020-B | self-avoiding molecular recognition system for DNA amplification | BENNER STEVEN ALBERT | 2015-04-29 | — | — | CN | disclosed |
| EP-1590361-B1 | PROCESS FOR PURIFYING OLIGONUCLEOTIDE SYNTHONS | NITTO DENKO AVECIA INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8916536-B2 | Bone-targeting bisphosphonate duplex drugs | SCHOTT HERBERT (DE) | 2014-12-23 | — | — | US | disclosed |
| WO-2014179335-A1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2014-11-06 | — | — | WO | disclosed |
| US-8877801-B2 | Compounds and compositions as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877801-B2 | Compounds and compositions as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8871469-B1 | Self-avoiding molecular recognition systems in DNA priming | BENNER STEVEN ALBERT (US) | 2014-10-28 | — | — | US | disclosed |
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2601202-B1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-20140235660-A1 | COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140235660-A1 | COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| WO-2014088519-A1 | COMPOUNDS INCLUDING MAP KINASE INTERACTING KINASES 1 AND 2 (MNK1 AND MNK2) MODULATORS AND ABL AND ABL (T315I) INHIBITORS, AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2014-06-12 | — | — | WO | disclosed |
| EP-2722335-A1 | PROCESS FOR PREPARING PHOSPHATE COMPOUND BEARING ISOTOPE | Bonac Corporation (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140100362-A1 | Process for Preparing Phosphate Compound Bearing Isotope | BONAC CORPORATION (JP) | 2014-04-10 | — | — | US | disclosed |
| WO-2014055548-A1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| CN-103517913-A | Method for producing phosphate compound having isotope | BONAC CORP | 2014-01-15 | — | — | CN | disclosed |
| EP-2654758-A1 | A COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3-DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR SUFFERING FROM IMMUNE REJECTION OF ORGANS | Idogen AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130237494-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2013-09-12 | — | — | US | disclosed |
| EP-2221311-B1 | Novel nucleic acid base pair | TAGCYX BIOTECHNOLOGIES (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2601202-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT, Herbert (DE) | 2013-06-12 | — | — | EP | disclosed |
| EP-2321332-B1 | SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION | BENNER STEVEN A (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130052690-A1 | PCR PRIMER AND METHOD FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION USING A PHOTOLABILE PROTECTING GROUP | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| EP-2560982-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | Chemgenes Corporation (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1501851-B1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | NITTO DENKO AVECIA INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8354225-B1 | Amplification of oligonucleotides containing non-standard nucleobases | BENNER STEVEN ALBERT (US) | 2013-01-15 | — | — | US | disclosed |
| US-8344118-B2 | Preparation and isolation of 5′ capped MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344118-B2 | Preparation and isolation of 5′ capped MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | Life Technologies Corporation (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | Life Technologies Corporation (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012087234-A1 | A COMPOSITION COMPRISING AT LEAST TO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3-DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR SUFFERING FROM IMMUNE REJECTION OF ORGANS | IDOGEN AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | disclosed |
| US-8193337-B2 | Oxidation process | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2012016994-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-8093367-B2 | Preparation and isolation of 5′ capped mRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093367-B2 | Preparation and isolation of 5′ capped mRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093397-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2398815-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | Chemgenes Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110300142-A1 | USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | IDOGEN AB (SE) | 2011-12-08 | — | — | US | disclosed |
| US-8008488-B2 | Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2011-08-30 | — | — | US | disclosed |
| US-8008488-B2 | Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2011-08-30 | — | — | US | disclosed |
| WO-2011103468-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | CHEMGENES CORPORATION (US) | 2011-08-25 | — | — | WO | disclosed |
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| CN-102124020-A | Self-avoiding molecular recognition system for DNA amplification | ALBERT BENNER STEVEN | 2011-07-13 | — | — | CN | disclosed |
| US-7960542-B2 | Process for purifying oligonucleotide synthons | AVECIA BIOTECHNOLOGY, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | CHEMGENES CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2326656-A2 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | Chemgenes Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2321332-A1 | SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION | Benner, Steven A. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7872121-B2 | Process for the removal of exocyclic base protecting groups | AVECIA BIOTECHNOLOGY, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| EP-1575975-B1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010096201-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100137572-A1 | OXIDATION PROCESS | NITTO DENKO AVECIA, INC. | 2010-06-03 | — | — | US | disclosed |
| WO-2010021702-A9 | SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION | BENNER STEVEN ALBERT (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010027512-A9 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORPORATION (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2164500-A1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | Idogen AB (SE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010027512-A2 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010021702-A1 | SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION | BENNER STEVEN ALBERT (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009868-A1 | Self-Assembled Combinatorial Encoding Nanoarrays for Multiplexed Biosensing | The Arizona Board of Regents a body corporate acti ng for and behalf of Arizona State university (US) | 2010-01-14 | — | — | US | disclosed |
| US-7635772-B2 | Process for the preparation of oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090221810-A1 | PROCESS FOR THE REMOVAL OF EXOCYCLIC BASE PROTECTING GROUPS | NITTO DENKO AVECIA, INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009058911-A2 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090085006-A1 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7501505-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1551812-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090054250-A1 | Methods to create fluorescent biosensors using aptamers with fluorescent base analogs | ARIZONA BOARD OF REGENTS, A CORPORATE BODY ORGANIZED UNDER ARIZONA LAW, ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY | 2009-02-26 | — | — | US | disclosed |
| WO-2009007736-A1 | OXIDATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-7476709-B2 | Process for preparing oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-01-13 | — | — | US | disclosed |
| WO-2008147283-A1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | SALFORD LEIF (SE) | 2008-12-04 | — | — | WO | disclosed |
| CN-100430411-C | Activators for oligonucleotide synthesis | AVECIA LTD (US) | 2008-11-05 | — | — | CN | disclosed |
| EP-1737877-B1 | PROCESS FOR THE REMOVAL OF EXOCYCLIC BASE PROTECTING GROUPS | AVECIA BIOTECHNOLOGY INC (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008033848-A2 | SELF-ASSEMBLED COMBINATORIAL ENCODING NANOARRAYS FOR MULTIPLEXED BIOSENSING | THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1601659-B1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2008-01-16 | — | — | EP | disclosed |
| CN-100344645-C | Process for purifying oligonucleotide synthons | AVECIA LTD (US) | 2007-10-24 | — | — | CN | disclosed |
| US-7247720-B2 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1554300-B1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070004911-A1 | Silylated oligonucleotide compounds | AVECIA LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ABBOT GMBH & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
| US-20060189799-A1 | Method of preventing modification of synthetic oligonucleotides | SINHA NANDA D | 2006-08-24 | — | — | US | disclosed |
| WO-2006078337-A2 | METHODS TO CREATE FLUORESCENT BIOSENSORS USING APTAMERS WITH FLUORESCENT BASE ANALOGS | THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060149052-A1 | Process for the preparation of oligonucleotides | AVECIA LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-20060135760-A1 | Process for purifying oligonucleotide synthons | NITTO DENKO AVECIA, INC. | 2006-06-22 | — | — | US | disclosed |
| US-7038027-B2 | Method of preventing modification of synthetic oligonucleotides | AVECIA BIOTECHNOLOGY, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060069247-A1 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2006-03-30 | — | — | US | disclosed |
| US-20060041114-A1 | Activators for oligonucleotide synthesis | NITTO DENKO AVECIA, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20060036028-A1 | Process for preparing oligonucleotides | NITTO DENKO AVECIA, INC. | 2006-02-16 | — | — | US | disclosed |
| US-20060035224-A1 | Purification methods for oligonucleotides and their analogs | AVECIA IPC INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1404696-B1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC (US) | 2006-02-08 | — | — | EP | disclosed |
| CN-1726223-A | Process for purifying oligonucleotide synthons | AVECIA LTD (GB) | 2006-01-25 | — | — | CN | disclosed |
| EP-1608669-A1 | SILYLATED OLIGONUCLEOTIDE COMPOUNDS | Avecia Limited (GB) | 2005-12-28 | — | — | EP | disclosed |
| EP-1601659-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2005-12-07 | — | — | EP | disclosed |
| EP-1590361-A2 | PROCESS FOR PURIFYING OLIGONUCLEOTIDE SYNTHONS | Avecia Limited (GB) | 2005-11-02 | — | — | EP | disclosed |
| EP-1575975-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | Avecia Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| CN-1649889-A | Process for preparing oligonucleotides | AVECIA LTD (GB) | 2005-08-03 | — | — | CN | disclosed |
| EP-1554300-A1 | PHOSPHITYLATION PROCESS | Avecia Biotechnology, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| CN-1643145-A | Purification methods for oligonucleotides and their analogs | AVECIA BIOTECHNOLOGY INC (US) | 2005-07-20 | — | — | CN | disclosed |
| US-6897027-B2 | Method for desalting nucleic acids | DECODE GENETICS EHF. (IS) | 2005-05-24 | — | — | US | disclosed |
| EP-1317466-B1 | SYNTHONS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC (US) | 2005-02-23 | — | — | EP | disclosed |
| EP-1501851-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | Avecia Limited (GB) | 2005-02-02 | — | — | EP | disclosed |
| EP-1490488-A2 | PURIFICATION METHODS FOR OLIGONUCLEOTIDES AND THEIR ANALOGS | Avecia Biotechnology Inc (US) | 2004-12-29 | — | — | EP | disclosed |
| CN-1549820-A | Activators for oligonucleotide synthesis | ƽ | 2004-11-24 | — | — | CN | disclosed |
| WO-2004085454-A1 | SILYLATED OLIGONUCLEOTIDE COMPOUNDS | AVECIA LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004080981-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004055036-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004055037-A2 | PROCESS FOR PURIFYING OLIGONUCLEOTIDE SYNTHONS | AVECIA LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| US-6752944-B2 | CATALYTICALLY CROSSLINKED WITH GLYOXAL AND, OPTIONALLY, A GLYCOL; DIAPERS; LIQUID RETENTION | WEYERHAEUSER COMPANY | 2004-06-22 | — | — | US | disclosed |
| WO-2004035599-A1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1404696-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-6703125-B2 | CELLULOSIC FIBERS TREATED WITH GLYOXAL AND A CROSSLINKING CATALYST | WEYERHAEUSER.COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229218-A1 | Synthons for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003091267-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| US-20030186247-A1 | Method for desalting nucleic acids | DECODE GENETICS EHF. (IS) | 2003-10-02 | — | — | US | disclosed |
| WO-2003080834-A2 | PURIFICATION METHODS FOR OLIGONUCLEOTIDES AND THEIR ANALOGS | AVECIA BIOTECHNOLOGY INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| CN-1444595-A | Deprotection of synthetic oligonucleotides using acrylonitrile scavenger | AVECIA BIOTECHNOLOGY INC (US) | 2003-09-24 | — | — | CN | disclosed |
| US-20030108742-A1 | High-wet-bulk cellulosic fibers | WEYERHAEUSER COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1317466-A2 | SYNTHONS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003045969-A1 | COUPLING REAGENT FOR H-PHOSPHONATE CHEMISTRY | AVECIA BIOTECHNOLOGY INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-6551706-B1 | High-wet-bulk cellulosic fibers | WEYERHAEUSER COMPANY | 2003-04-22 | — | — | US | disclosed |
| EP-1294736-A1 | DEPROTECTION OF SYNTHETIC OLIGONUCLEOTIDES USING AN ACRYLONITRILE SCAVENGER | Avecia Biotechnology, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2003004512-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| US-20030008580-A1 | High-wet-bulk cellulosic fibers | WEYERHAEUSER COMPANY | 2003-01-09 | — | — | US | disclosed |
| US-20020072593-A1 | Method of preventing modification of synthetic oligonucleotides | AVECIA BIOTECHNOLOGY INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2002020543-A2 | SYNTHONS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001096358-A1 | DEPROTECTION OF SYNTHETIC OLIGONUCLEOTIDES USING ACRYLONITRILE SCAVENGER | AVECIA BIOTECHNOLOGY, INC. (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1149200-A1 | HIGH-WET-BULK CELLULOSIC FIBERS | WEYERHAEUSER COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| US-6207278-B1 | CROSSLINKING CELLULOSE WITH GLYOXAL, PROPYLENE GLYCOL, ALUMINUM SULFATE AND CITRIC ACID | WEYERHAEUSER COMPANY | 2001-03-27 | — | — | US | disclosed |
| WO-2000044977-A1 | HIGH-WET-BULK CELLULOSIC FIBERS | WEYERHAEUSER COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-1993017651-A2 | ANTIVIRAL NUCLEOSIDE ANALOGUES, THEIR PRODUCTION AND USE | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 1993-09-16 | — | — | WO | disclosed |
| EP-0132127-B1 | CYCLIC UREA CONDENSATES, TEXTILE AND PAPER TREATING COMPOSITIONS AND NOVEL CYCLIC UREAS | SEQUA CHEMICALS INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| US-5126439-A | Complementary purines and pyrimidines | TEMPLE UNIVERSITY (US) | 1992-06-30 | — | — | US | disclosed |
| EP-0333832-B1 | ARTIFICIAL DNA BASE PAIR ANALOGUES | TEMPLE UNIVERSITY (US) | 1992-06-03 | — | — | EP | disclosed |
| EP-0206588-B1 | COPOLYMER BINDER COMPOSITION AND FABRICS AND PAPERS TREATED THEREWITH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-09-12 | — | — | EP | disclosed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | disclosed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | disclosed |
| EP-0355031-A2 | Substituted pyrimidine nucleosides, process for their preparation and pharmaceutical compounds containing them | MATTHES, Eckart, Dr. (DE) | 1990-02-21 | — | — | EP | disclosed |
| EP-0333832-A1 | ARTIFICIAL DNA BASE PAIR ANALOGUES | TEMPLE UNIVERSITY (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4847143-A | ADDITION POLYMER,GLYOXAL RESIN, METAL SALT CATALYST, AND SULFATE SURFACTANT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-07-11 | — | — | US | disclosed |
| WO-1989002921-A1 | ARTIFICIAL DNA BASE PAIR ANALOGUES | TEMPLE UNIVERSITY (US) | 1989-04-06 | — | — | WO | disclosed |
| EP-0206588-A1 | Copolymer binder composition and fabrics and papers treated therewith | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4505712-A | Cyclic urea/glyoxal/polyol condensates and their use in treating textile fabrics and paper | SUN CHEMICAL CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
| EP-0132127-A2 | Cyclic urea condensates, textile and paper treating compositions and novel cyclic ureas | SEQUA CHEMICALS INC. (US) | 1985-01-23 | — | — | EP | disclosed |
| US-4455416-A | INSOLUBILIZERS | SUN CHEMICAL CORPORATION (US) | 1984-06-19 | — | — | US | disclosed |
| US-4455416-A | INSOLUBILIZERS | SUN CHEMICAL CORPORATION (US) | 1984-06-19 | — | — | US | disclosed |